Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04575181 | A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine | PHASE1 | COMPLETED | 86 | — | — | Oct 21, 2020 | Dec 24, 2021 | Jan 10, 2024 | 2 | Germany |
| NCT04136067 | A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes | PHASE1 | COMPLETED | 36 | — | — | Oct 29, 2019 | Aug 23, 2020 | Sep 8, 2022 | 1 | Germany |
Percent
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0286-0965 | EXPERIMENTAL | NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial |
| Insulin glargine | ACTIVE_COMPARATOR | Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial |
| NNC0268-0965 | EXPERIMENTAL | Participants will receive NNC0268-0965 |
| Name | Type | Description |
|---|---|---|
| NNC0268-0965 | DRUG | For subcutaneous (s.c., under the skin) injection once daily for 26 weeks |
| Insulin glargine | DRUG | For s.c. injection once daily for 26 weeks |
| Placebo (NNC0268-0965) | DRUG | For s.c. injection once daily for 26 weeks |
| Placebo (insulin glargine) | DRUG | For s.c. injection once daily for 26 weeks |
Inclusion Criteria: * Informed consent obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Aged 40-75 years (both inclusive) at the time of signing informe...